FindTrial
Sign In

Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

BIOLOGICAL4 trials

Sponsors

Beijing Health Guard Biotechnology, Inc

Conditions

Human Papilloma Virus InfectionHuman Papillomavirus Infection

Phase 1

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
CompletedNCT05680454
Beijing Health Guard Biotechnology, IncHuman Papillomavirus Infection
Start: 2019-09-01End: 2022-05-10Updated: 2023-01-17

Phase 2

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
CompletedNCT05694728
Beijing Health Guard Biotechnology, IncHuman Papilloma Virus Infection
Start: 2020-05-23End: 2021-01-27Updated: 2023-01-23

Phase 3

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Active, not recruitingNCT05662020
Beijing Health Guard Biotechnology, IncHuman Papillomavirus Infection
Start: 2022-03-23End: 2028-03-23Updated: 2022-12-27
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
NCT05668572
Beijing Health Guard Biotechnology, IncHuman Papillomavirus Infection
Start: 2020-12-05End: 2023-02-23Updated: 2023-01-04

Related Papers

Immunogenicity and safety of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20-45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial.
2025-11-14